Osimertinib-induced cardiopulmonary toxicity: a network toxicology, molecular docking, and molecular dynamics simulation study

Abstract Context: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is first-line therapy for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). However, its clinical utility is severely limited by significant cardiotoxicity and pulmotoxicity, which compromise treatment adherence and patient survival. The shared molecular pathogenesis underlying these concurrent adverse effects remains unclear and warrants systematic investigation. Methods We employed an integrated computational framework combining network toxicology, molecular docking, and molecular dynamics (MD) simulations. Multi-database screening identified 119 shared targets between osimertinib and cardiopulmonary toxicity, from which seven hub targets—TP53, ESR1, HDAC1, CREBBP, EP300, HDAC2, and SMARCA4—were prioritized. Enrichment analysis implicated these targets in epigenetic regulation and cancer-related pathways such as microRNAs in cancer. Molecular docking confirmed high-affinity binding of osimertinib to all hub targets (binding free energies − 6.4 to -7.2 kcal/mol). MD simulations demonstrated stable binding with HDAC1 and CREBBP (-20.85 and − 22.92 kcal/mol, respectively) and identified key interacting residues. This work outlines a multi-target, multi-pathway regulatory network and proposes an epigenetics-centered hypothesis: osimertinib-induced cardiopulmonary toxicity may arise from disruption of the CREBBP/EP300-HDAC1/HDAC2 epigenetic balance together with TP53-, ESR1-, and SMARCA4-mediated interactions, providing a theoretical basis for future experimental validation and therapeutic modulation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11304777/v1
Primary Topic
Computational Drug Discovery Methods
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Osimertinib-induced cardiopulmonary toxicity: a network toxicology, molecular docking, and molecular dynamics simulation study

Jiajia Shao, Enfu Tao, Huihui Yang, Jiawei Han et al.
6 links
Research Square
Computational Drug Discovery Methods
preprint

Osimertinib-induced cardiopulmonary toxicity: a network toxicology, molecular docking, and molecular dynamics simulation study

Jiajia Shao, Enfu Tao, Huihui Yang, Jiawei Han, Jiayi Zhong
preprint en

Abstract

Abstract Context: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is first-line therapy for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). However, its clinical utility is severely limited by significant cardiotoxicity and pulmotoxicity, which compromise treatment adherence and patient survival. The shared molecular pathogenesis underlying these concurrent adverse effects remains unclear and warrants systematic investigation. Methods We employed an integrated computational framework combining network toxicology, molecular docking, and molecular dynamics (MD) simulations. Multi-database screening identified 119 shared targets between osimertinib and cardiopulmonary toxicity, from which seven hub targets—TP53, ESR1, HDAC1, CREBBP, EP300, HDAC2, and SMARCA4—were prioritized. Enrichment analysis implicated these targets in epigenetic regulation and cancer-related pathways such as microRNAs in cancer. Molecular docking confirmed high-affinity binding of osimertinib to all hub targets (binding free energies − 6.4 to -7.2 kcal/mol). MD simulations demonstrated stable binding with HDAC1 and CREBBP (-20.85 and − 22.92 kcal/mol, respectively) and identified key interacting residues. This work outlines a multi-target, multi-pathway regulatory network and proposes an epigenetics-centered hypothesis: osimertinib-induced cardiopulmonary toxicity may arise from disruption of the CREBBP/EP300-HDAC1/HDAC2 epigenetic balance together with TP53-, ESR1-, and SMARCA4-mediated interactions, providing a theoretical basis for future experimental validation and therapeutic modulation.

Research Square
Weifang Maternity and Child Care Hospital (CN)
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon